Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Fut and Edig

Sedley,

I assume you are referring to the latest info out that said the o/s shares was now 380 million. You might be right. But then right before the 10q came out some posters were up in arms because some thought more shares had been issued, when in reality the outstanding had gone up because of warrant conversion. IMO that's not dilution since the fully diluted amount of shares didn't go up as a result. That may also be the case now. If I remember correctly the info was stated that "as of November 3 the outstanding was 380 million". Point being "as of November 3".

Share
New Message
Please login to post a reply